We have located links that may give you full text access.
18F-fluorodeoxyglucose positron emission tomography (18FDG-PET) for patients with biliary tract cancer: systematic review and meta-analysis.
Journal of Hepatology 2019 Februrary 21
INTRODUCTION: The role of 18 F-fluorodeoxyglucose positron emission tomography (18 FDG-PET) in the diagnosis and staging of patients with biliary tract cancer (BTCs) remains controversial.
METHODS: This systematic-review and meta-analysis explored the diagnostic test accuracy (DTA) of 18 FDG-PET as a diagnostic tool for diagnosis of primary tumour (T), lymph node (N), distant metastases (M) and relapsed disease (Rel). Subgroup analysis by study quality and BTC subtype were performed. Changes in management based on 18 FDG-PET and impact of maximum standardized uptake values (SUVmax) on prognosis were also assessed. Random effects model was used for meta-analyses (MataDiSc v.1.4; Stata v.12; RevMan v.5; R-Studio v.8.1).
RESULTS: Of 47 eligible studies, 2,125 patients were included. Pooled sensitivity (Se) and specificity (Sp) for patients with BTC were: T [Se 91.7% (95% CI 89.8-93.2); Sp 51.3% (95% CI 46.4-56.2); area under the curve (AUC) 0.8668]; N [Se 88.4% (95% CI 82.6-92.8); Sp 69.1%(95% CI 63.8-74.1); AUC 0.8519]; M [Se 85.4% (95% CI 79.5-90.2); Sp 89.7%(95% CI 86.0-92.7); AUC 0.9253]; Rel [Se 90.1% (95% CI 84.4-94.3); Sp 83.5%(95% CI 74.4-90.4); AUC 0.9592]. No threshold effect was identified. Meta-regression did not identify significant sources of heterogeneity. Sensitivity analysis did not reveal changes in results when analyses were limited to studies with low risk of bias/concern (high quality). Pooled proportion of change in management was 15% (95% CI 11-20); majority (78%) due to disease upstaging. Baseline high SUVmax was associated with worse survival (pooled HR of 1.79 (95% CI 1.37-2.33); p-value <0.001).
CONCLUSIONS: There is evidence to support the incorporation of 18 FDG-PET to the current standard of care staging imaging/diagnostic tests performed for the assessment of N, M and Rel to guide adequate treatment selection; especially if the identification of occult sites of disease would change management (i.e. surgery/local therapies) or if diagnosis of Rel remains unclear following standard of care imaging. The use of 18 FDG-PET for diagnosis of primary tumour (T) in the absence of other disease sites or pathological confirmation remains controversial, due to low specificity.
LAY SUMMARY: A positron emission tomography (PET scan), using 18F-fluorodeoxyglucose (18FDG), can help doctors identify areas of cancer in the body by highlighting "hot spots". These hotspots may be cancerous (true positive) but may also be non-cancerous, like inflammation (false positive). In this study all the published research of PET scans in patients with biliary tract cancer has been reviewed (systematic analysis) and the available information studied together (meta-analysis). We show that PET scans are useful to assess how far advanced the cancer is (by assessing spread to lymph glands and to other organs); and also useful to identify if the cancer has recurred (for example after surgery), thus helping doctors to make treatment decisions. However, it is not useful to first diagnose a biliary tract cancer due to the high chances of a "false positive" (diagnosing a cancer when there isn't one). Therefore, doctors should not rely on 18FDG-PET for diagnosis; a biopsy is still necessary.
METHODS: This systematic-review and meta-analysis explored the diagnostic test accuracy (DTA) of 18 FDG-PET as a diagnostic tool for diagnosis of primary tumour (T), lymph node (N), distant metastases (M) and relapsed disease (Rel). Subgroup analysis by study quality and BTC subtype were performed. Changes in management based on 18 FDG-PET and impact of maximum standardized uptake values (SUVmax) on prognosis were also assessed. Random effects model was used for meta-analyses (MataDiSc v.1.4; Stata v.12; RevMan v.5; R-Studio v.8.1).
RESULTS: Of 47 eligible studies, 2,125 patients were included. Pooled sensitivity (Se) and specificity (Sp) for patients with BTC were: T [Se 91.7% (95% CI 89.8-93.2); Sp 51.3% (95% CI 46.4-56.2); area under the curve (AUC) 0.8668]; N [Se 88.4% (95% CI 82.6-92.8); Sp 69.1%(95% CI 63.8-74.1); AUC 0.8519]; M [Se 85.4% (95% CI 79.5-90.2); Sp 89.7%(95% CI 86.0-92.7); AUC 0.9253]; Rel [Se 90.1% (95% CI 84.4-94.3); Sp 83.5%(95% CI 74.4-90.4); AUC 0.9592]. No threshold effect was identified. Meta-regression did not identify significant sources of heterogeneity. Sensitivity analysis did not reveal changes in results when analyses were limited to studies with low risk of bias/concern (high quality). Pooled proportion of change in management was 15% (95% CI 11-20); majority (78%) due to disease upstaging. Baseline high SUVmax was associated with worse survival (pooled HR of 1.79 (95% CI 1.37-2.33); p-value <0.001).
CONCLUSIONS: There is evidence to support the incorporation of 18 FDG-PET to the current standard of care staging imaging/diagnostic tests performed for the assessment of N, M and Rel to guide adequate treatment selection; especially if the identification of occult sites of disease would change management (i.e. surgery/local therapies) or if diagnosis of Rel remains unclear following standard of care imaging. The use of 18 FDG-PET for diagnosis of primary tumour (T) in the absence of other disease sites or pathological confirmation remains controversial, due to low specificity.
LAY SUMMARY: A positron emission tomography (PET scan), using 18F-fluorodeoxyglucose (18FDG), can help doctors identify areas of cancer in the body by highlighting "hot spots". These hotspots may be cancerous (true positive) but may also be non-cancerous, like inflammation (false positive). In this study all the published research of PET scans in patients with biliary tract cancer has been reviewed (systematic analysis) and the available information studied together (meta-analysis). We show that PET scans are useful to assess how far advanced the cancer is (by assessing spread to lymph glands and to other organs); and also useful to identify if the cancer has recurred (for example after surgery), thus helping doctors to make treatment decisions. However, it is not useful to first diagnose a biliary tract cancer due to the high chances of a "false positive" (diagnosing a cancer when there isn't one). Therefore, doctors should not rely on 18FDG-PET for diagnosis; a biopsy is still necessary.
Full text links
Related Resources
Trending Papers
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Anti-Arrhythmic Effects of Heart Failure Guideline-Directed Medical Therapy and Their Role in the Prevention of Sudden Cardiac Death: From Beta-Blockers to Sodium-Glucose Cotransporter 2 Inhibitors and Beyond.Journal of Clinical Medicine 2024 Februrary 27
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app